Top analyst says the tempest over drug prices will likely just die out without any major changes
Leerink’s Geoffrey Porges is taking a bullish view on large cap biopharma companies’ chances for the rest of the year.
After watching stocks suffer through …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
